Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas

Area of Science:

• Gastroenterology
• Endocrinology
• Oncology

Background:

• Octreotide's efficacy in endocrine tumor secretion is known, but its impact on neuroendocrine tumor generation and cell proliferation requires further investigation.
• Enterochromaffin-like (ECL) cells are implicated in gastric tumor development.
• Understanding the role of somatostatin receptor blockade in modulating gastrin levels and ECL cell proliferation is crucial.

Purpose of the Study:

• To investigate the effect of octreotide, a somatostatin receptor antagonist, on gastrin levels.
• To determine if octreotide influences enterochromaffin-like (ECL) cell proliferation.
• To evaluate the efficacy of octreotide in a rodent model of gastric ECLoma.

Main Methods:

• Utilized the mastomys rodent model, a well-established gastric ECLoma model.
• Administered loxtidine (H2 blocker) and octreotide (150 or 300 µg/kg/day) via slow-release pellets for 4 months.
• Monitored gastric mucosal thickness, plasma gastrin levels, ECL cell density, and bromodeoxyuridine-positive cells.

Main Results:

• Loxtidine treatment significantly increased gastric mucosal thickness, plasma gastrin, ECL cell density, and cell proliferation.
• High-dose octreotide significantly inhibited all measured parameters, including gastric mucosal thickness, gastrin levels, ECL cell density, and proliferation.
• Low-dose octreotide did not significantly inhibit ECL cell density, mucosal thickness, or cell proliferation.

Conclusions:

• Irreversible H2 receptor blockade induces hypergastrinemia and ECL cell tumor generation.
• In vivo blockade of somatostatin receptors by octreotide significantly inhibits hypergastrinemia, ECL cell hyperplasia, and cell proliferation.
• Octreotide demonstrates potential as a therapeutic agent for conditions involving hypergastrinemia and ECL cell proliferation.